HIV-1 gp41 as a target for viral entry inhibition

Current Pharmaceutical Design

Volumn 10, Issue 15, 2004, Pages 1805-1825

  Root, Michael J ^a   Steger, H Kirby ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

2F5; C peptides; gp41; HR1 pocket; Membrane fusion; N coiled coil inhibitors; N peptides; T 20; Trimer of hairpins

Indexed keywords

ADSJ 1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C 34; CD4 ANTIGEN; CHEMOKINE RECEPTOR; D 10; DP 107; DPN 107; ENFUVIRTIDE; EPITOPE; FORMAZAN; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IQN 23; M 87; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY Z13; N 36; NEUTRALIZING ANTIBODY; PEPTIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; BACTERIAL PNEUMONIA; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INJECTION SITE REACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS INHIBITION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 2442625211     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384448     Document Type: Review

References (203)

1. Richman DD. HIV chemotherapy. Nature 2001; 410: 995-1001.
2. Moore JP, Stevenson M. New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000; 1: 40-49.
3. White JM. Membrane fusion: the influenza paradigm. Cold Spring Harb Symp Quant Biol 1995; 60: 581-588.
4. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69: 531-569.
5. Hughson FM. Enveloped viruses: a common mode of membrane fusion? Curr Biol 1997; 7: R565-569.
6. Hernandez LD, Hoffman LR, Wolfsberg TG, White JM. Virus-cell and cell-cell fusion. Annu Rev Cell Dev Biol 1996; 12: 627-661.
7. Melikyan GB, Chernomordik LV. Membrane rearrangements in fusion mediated by viral proteins. Trends Microbiol 1997; 5: 349- 355.
8. Chernomordik LV, Leikina E, Kozlov MM, Frolov VA, Zimmerberg J. Structural intermediates in influenza haemagglutinin-mediated fusion. Mol Membr Biol 1999; 16: 33-42.
9. Pecheur EI, Sainte-Marie J, Bienvenue A, Hoekstra D. Peptides and membrane fusion: towards an understanding of the molecular mechanism of protein-induced fusion. J Membr Biol 1999; 167: 1- 17.
10. Skehel JJ, Wiley DC. Coiled coils in both intracellular vesicle and viral membrane fusion. Cell 1998; 95: 871-874.
11. Weissenhorn W, Dessen A, Calder LJ, Harrison SC, Skehel JJ, Wiley DC. Structural basis for membrane fusion by enveloped viruses. Mol Membr Biol 1999; 16: 3-9.
12. Epand RM. Fusion peptides and the mechanism of viral fusion. Biochim Biophys Acta 2003; 1614: 116-121.
13. Colman PM, Lawrence MC. The structural biology of type 1 viral membrane fusion. Nat Rev Mol Cell Biol 2003; 4: 309-319.
14. Blumenthal R, Clague MJ, Durell SR, Epand RM. Membrane fusion. Chem Rev 2003; 103: 53-69.
15. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70: 777-810.
16. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393: 705-711.
17. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
18. Littman DR. Chemokine receptors: keys to AIDS pathogenesis? Cell 1998; 93: 677-680.
19. Este JA. Virus entry as a target for anti-HIV intervention. Curr Med Chem 2003; 10: 1617-1632.
20. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998; 93: 681-684.
21. D'Souza MP, Cairns JS, Plaeger SF. Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies. JAMA 2000; 284: 215-222.
22. Doms RW, Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 2000; 14: 2677-2688.
23. LaBranche CC, Galasso G, Moore JP, Bolognesi DP, Hirsch MS, Hammer SM. HIV fusion and its inhibition. Antiviral Res 2001; 50: 95-115.
24. Freed EO, Martin MA. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 1995; 270: 23883-23886.
25. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, et al. The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003; 1614: 36-50.
26. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003; 348: 2228-2238.
27. Earl PL, Moss B, Doms RW. Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol 1991; 65: 2047-2055.
28. Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, et al. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 1987; 237: 1351-1355.
29. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, Reyes GR, et al. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 1988; 53: 55-67.
30. Yang X, Farzan M, Wyatt R, Sodroski J. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2000; 74: 5716-5725.
31. Farzan M, Choe H, Desjardins E, Sun Y, Kuhn J, Cao J, et al. Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J Virol 1998; 72: 7620-7625.
32. Center RJ, Kemp BE, Poumbourios P. Human immunodeficiency virus type 1 and 2 envelope glycoproteins oligomerize through conserved sequences. J Virol 1997; 71: 5706-5711.
33. Poumbourios P, Wilson KA, Center RJ, El Ahmar W, Kemp BE. Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence. J Virol 1997; 71: 2041-2049.
34. O'Shea EK, Rutkowski R, Kim PS. Evidence that the leucine zipper is a coiled coil. Science 1989; 243: 538-542.
35. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2: 1075-1082.
36. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89: 263-273.
37. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387: 426-430.
38. Tan K, Liu J, Wang J, Shen S, Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 1997; 94: 12303-12308.
39. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990; 265: 10373-10382.
40. Fenouillet E, Jones IM. The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160. J Gen Virol 1995; 76 (Pt 6): 1509-1514.
41. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-312.
42. Johnson WE, Sauvron JM, Desrosiers RC. Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication. J Virol 2001; 75: 11426-11436.
43. Perrin C, Fenouillet E, Jones IM. Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein. Virology 1998; 242: 338-345.
44. Fenouillet E, Gluckman JC, Jones IM. Functions of HIV envelope glycans. Trends Biochem Sci 1994; 19: 65-70.
45. Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis. Proc Natl Acad Sci USA 2003; 100: 10592-10597.
46. Nguyen DG, Booth A, Gould SJ, Hildreth JE. Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J Biol Chem 2003.
47. Murakami T, Freed EO. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol 2000; 74: 3548-3554.
48. Murakami T, Freed EO. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci USA 2000; 97: 343-348.
49. Cosson P. Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J 1996; 15: 5783-5788.
50. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312: 763-767.
51. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312: 767-768.
52. Doranz BJ, Baik SS, Doms RW. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol 1999; 73: 10346-10358.
53. Salzwedel K, Smith ED, Dey B, Berger EA. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 2000; 74: 326-333.
54. Jones PL, Korte T, Blumenthal R. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem 1998; 273: 404-409.
55. Sattentau QJ, Zolla-Pazner S, Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 1995; 206: 713-717.
56. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996; 384: 184-187.
57. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993; 67: 3978-3988.
58. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384: 179-183.
59. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990; 250: 1139-1142.
60. Clements GJ, Price-Jones MJ, Stephens PE, Sutton C, Schulz TF, Clapham PR, et al. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses 1991; 7: 3-16.
61. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS, Golding H. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 1996; 274: 602-605.
62. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877.
63. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-673.
64. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955-1958.
65. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-1148.
66. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85: 1149-1158.
67. Kliger Y, Aharoni A, Rapaport D, Jones P, Blumenthal R, Shai Y. Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell Fusion. Structure-function study. J Biol Chem 1997; 272: 13496- 13505.
68. Dimitrov AS, Xiao X, Dimitrov DS, Blumenthal R. Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes. J Biol Chem 2001; 276: 30335-30341.
69. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-659.
70. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des 2000; 8: 1329-1339.
71. Guo Q, Ho HT, Dicker I, Fan L, Zhou N, Friborg J, et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 2003; 77: 10528-10536.
72. Blacklow SC, Lu M, Kim PS. A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry 1995; 34: 14955-14962.
73. Caffrey M, Cai M, Kauftnan J, Stahl SJ, Wingfield PT, Covell DG, et al. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. Embo J 1998; 17: 4572-4584.
74. Yang ZN, Mueser TC, Kaufman J, Stahl SJ, Wingfield PT, Hyde CC. The crystal structure of the SIV gp41 ectodomain at 1.47 A resolution. J Struct Biol 1999; 126: 131-144.
75. Dong XN, Xiao Y, Dierich MP, Chen YH. N- and C-domains of HIV-1 gp41: mutation, structure and functions. Immunol Lett 2001; 75: 215-220.
76. Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor. Science 2001; 291: 884-888.
77. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999; 99: 103-115.
78. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998; 95: 15613-15617.
79. Dwyer JJ, Hasan A, Wilson KL, White JM, Matthews TJ, Delmedico MK. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 2003; 42: 4945-4953.
80. Ji H, Shu W, Burling FT, Jiang S, Lu M. Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol 1999; 73: 8578-8586.
81. Singh M, Berger B, Kim PS. LearnCoil-VMF: computational evidence for coiled-coil-like motifs in many viral membrane-fusion proteins. J Mol Biol 1999; 290: 1031-1041.
82. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994; 371: 37-43.
83. Chen J, Skehel JJ, Wiley DC. N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA(2) subunit to form an N cap that terminates the triple-stranded coiled coil. Proc Natl Acad Sci USA 1999; 96: 8967-8972.
84. Fass D, Harrison SC, Kim PS. Retrovirus envelope domain at 1.7 angstrom resolution. Nat Struct Biol 1996; 3: 465-469.
85. Weissenhorn W, Carfi A, Lee KH, Skehel JJ, Wiley DC. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 1998; 2: 605-616.
86. Malashkevich VN, Schneider BJ, McNally ML, Milhollen MA, Pang JX, Kim PS. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc Natl Acad Sci USA 1999; 96: 2662-2667.
87. Malashkevich VN, Singh M, Kim PS. The trimer-of-hairpins motif in membrane fusion: Visna virus. Proc Natl Acad Sci USA 2001; 98: 8502-8506.
88. Kobe B, Center RJ, Kemp BE, Poumbourios P. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc Natl Acad Sci USA 1999; 96: 4319-4324.
89. Zhao X, Singh M, Malashkevich VN, Kim PS. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci USA 2000; 97: 14172-14177.
90. Baker KA, Dutch RE, Lamb RA, Jardetzky TS. Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 1999; 3: 309-319.
91. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, Burton DR. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 2003; 77: 5678-5684.
92. Abrahamyan LG, Markosyan RM, Moore JP, Cohen FS, Melikyan GB. Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. J Virol 2003; 77: 5829-5836.
93. Weng Y, Weiss CD. Mutational analysis of residues in the coiledcoil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol 1998; 72: 9676-9682.
94. Weng Y, Yang Z, Weiss CD. Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J Virol 2000; 74: 5368-5372.
95. Cao J, Bergeron L, Helseth E, Thali M, Repke H, Sodroski J. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol 1993; 67: 2747-2755.
96. Follis KE, Larson SJ, Lu M, Nunberg JH. Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state. J Virol 2002; 76: 7356-7362.
97. Wang S, York J, Shu W, Stoller MO, Nunberg JH, Lu M. Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion. Biochemistry 2002; 41: 7283-7292.
98. Lu M, Stoller MO, Wang S, Liu J, Fagan MB, Nunberg JH. Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J Virol 2001; 75: 11146-11156.
99. Liu J, Shu W, Fagan MB, Nunberg JH, Lu M. Structural and functional analysis of the HIV gp41 core containing an Ile573 to Thr substitution: implications for membrane fusion. Biochemistry 2001; 40: 2797-2807.
100. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992; 89: 10537-10541.
101. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91: 9770-9774.
102. Jiang S, Lin K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. Nature 1993; 365: 113.
103. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998; 72: 986-993.
104. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000; 151: 413-423.
105. Debnath AK, Radigan L, Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem 1999; 42: 3203-3209.
106. Eckert DM, Kim PS. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci USA 2001; 98: 11187-11192.
107. Louis JM, Bewley CA, Clore GM. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 2001; 276: 29485-29489.
108. Wilson IA, Skehel JJ, Wiley DC. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981; 289: 366-373.
109. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 1988; 333: 426-431.
110. Ruigrok RW, Martin SR, Wharton SA, Skehel JJ, Bayley PM, Wiley DC. Conformational changes in the hemagglutinin of influenza virus which accompany beat-induced fusion of virus with liposomes. Virology 1986; 155: 484-497.
111. Skehel JJ, Bayley PM, Brown EB, Martin SR, Waterfield MD, White JM, et al. Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci USA 1982; 79: 968-972.
112. Carr CM, Kim PS. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 1993; 73: 823-832.
113. Carr CM, Chaudhry C, Kim PS. Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci USA 1997; 94: 14306-14313.
114. Carr CM, Kim PS. Flu virus invasion: halfway there. Science 1994; 266: 234-236.
115. Furuta RA, Wild CT, Weng Y, Weiss CD. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998; 5: 276-279.
116. Koshiba T, Chan DC. The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J Biol Chem 2003; 278: 7573-7579.
117. Root MJ, Hamer DH. Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein. Proc Natl Acad Sci USA 2003; 100: 5016-5021.
118. He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, Weng Y, et al. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003; 77: 1666-1671.
119. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 1998; 140: 315-323.
120. Moore JP, McKeating JA, Huang YX, Ashkenazi A, Ho DD. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 1992; 66: 235-243.
121. Munoz-Barroso I, Durell S, Sakaguichi K, Apella E, Blumenthal R. Dilation of the Human Immunodeficiency Virus-1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41. Journal of Cell Biology 1998; 140: 315-323.
122. Chan DC, Kim PS. HIV Entry and Its Inhibition. Cell 1998; 93: 681-684.
123. Gallo SA, Puri A, Blumenthal R. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry 2001; 40: 12231-12236.
124. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002; 99: 16249-16254.
125. Markosyan RM, Cohen FS, Melikyan GB. HIV-1 Envelope Proteins Complete Their Folding into Six-helix Bundles Immediately after Fusion Pore Formation. Mol Biol Cell 2003; 14: 926-938.
126. Golding H, Zaitseva M, de Rosny E, King LR, Manischewitz J, Sidorov I, et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 2002; 76: 6780-6790.
127. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46: 1896-1905.
128. Wild C, Greenwell T, Shugars D, Rimsky-Clarke L, Matthews T. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses 1995; 11: 323-325.
129. Kilgore NR, Salzwedel K, Reddick M, Allaway GP, Wild CT. Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J Virol 2003; 77: 7669-7672.
130. Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75: 8605-8614.
131. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74: 8358-8367.
132. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000; 25: 99-102.
133. Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002; 46: 1336-1339.
134. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003; 100: 10598-10602.
135. Trivedi VD, Cheng SF, Wu CW, Karthikeyan R, Chen CJ, Chang DK. The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng 2003; 16: 311-317.
136. Armand-Ugon M, Gutierrez A, Clotet B, Este JA. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res 2003; 59: 137-142.
137. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4: 1302-1307.
138. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18: 685-693.
139. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. Aids 2003; 17: 691-698.
140. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-2185.
141. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia, N Engl J Med 2003; 348: 2186-2195.
142. Tashima KT, Carpenter CC. Fusion inhibition--a major but costly step forward in the treatment of HIV-1. N Engl J Med 2003; 348: 2249-2250.
143. Lawless MK, Barney S, Guthrie KI, Bucy TB, Petteway SR Jr, Merutka G. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 1996; 35: 13697-13708.
144. Kliger Y, Gallo SA, Peisajovich SG, Munoz-Barroso I, Avkin S, Blumenthal R, et al. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem 2001; 276: 1391-1397.
145. Veiga S, Henriques ST, Santos NC, Castanho MA. Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem J 2004; 377: 107-110.
146. Barney S, Guthrie K, Kelly I, Merutka G, Mohmed K, Lambert D. Hybrid polypeptides with enhanced pharmacokinetic properties. Patent #6562787, in http://patft.uspto.gov 2001; Trimeris, Inc.
147. Hagihara Y, Kim PS. Toward development of a screen to identify randomly encoded, foldable sequences. Proc Natl Acad Sci USA 2002; 99: 6619-6624.
148. Hildinger M, Dittmar MT, Schult-Dietrich P, Fehse B, Schnierle BS, Thaler S, et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 2001; 75: 3038-3042.
149. Markosyan RM, Ma X, Lu M, Cohen FS, Melikyan GB. The mechanism of inhibition of HIV-1 env-mediated cell-cell fusion by recombinant cores of gp41 ectodomain. Virology 2002; 302: 174-184.
150. Shu W, Liu J, Ji H, Radigen L, Jiang S, Lu M. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 2000; 39: 1634-1642.
151. Lu M, Ji H, Shen S. Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion. J Virol 1999; 73: 4433-4438.
152. Sia SK, Kim PS. Protein grafting of an HIV-1-inhibiting epitope. Proc Natl Acad Sci USA 2003; 100: 9756-9761.
153. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989; 338: 254-257.
154. Zapp ML, Green MR. Sequence-specific RNA binding by the HIV-1 Rev protein. Nature 1989; 342: 714-716.
155. Jin BS, Ryu JR, Ahn K, Yu YG. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000; 16: 1797-1804.
156. Sia SK, Carr PA, Cochran AG, Malashkevich VN, Kim PS. Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci USA 2002; 99: 14664-14669.
157. Schumacher TN, Mayr LM, Minor DL Jr, Milhollen MA, Burgess MW, Kim PS. Identification of D-peptide ligands through mirror-image phage display. Science 1996; 271: 1854-1857.
158. Cole JL, Garsky VM. Thermodynamics of peptide inhibitor binding to HIV-1 gp41. Biochemistry 2001; 40: 5633-5641.
159. Zhao Q, Ernst JT, Hamilton AD, Debnath AK, Jiang S. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses 2002; 18: 989-997.
160. Ferrer M, Kapoor TM, Strassmaier T, Weissenhorn W, Skehel JJ, Oprian D, et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 1999; 6: 953-960.
161. Zhou G, Ferrer M, Chopra R, Kapoor TM, Strassmaier T, Weissenhorn W, et al. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg Med Chem 2000; 8: 2219-2227.
162. Wild C, Dubay JW, Greenwell T, Baird T Jr, Oas TG, McDanal C, et al. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA 1994; 91: 12676-12680.
163. Bewley CA, Louis JM, Ghirlando R, Clore GM. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 2002; 277: 14238-14245.
164. Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S, et al. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 2003; 77: 353-365.
165. McGinnes LW, Reitter JN, Gravel K, Morrison TG. Evidence for mixed membrane topology of the newcastle disease virus fusion protein. J Virol 2003; 77: 1951-1963.
166. Buratti E, McLain L, Tisminetzky S, Cleveland SM, Dimmock NJ, Baralle FE. The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J Gen Virol 1998; 79 (Pt 11): 2709-2716.
167. Cleveland SM, Jones TD, Dimmock NJ. Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1. J Gen Virol 2000; 81: 1251-1260.
168. Cleveland SM, McLain L, Cheung L, Jones TD, Hollier M, Dimmock NJ. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J Gen Virol 2003; 84: 591-602.
169. Burton DR. A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci USA 1997; 94: 10018-10023.
170. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67: 6642-6647.
171. Purtscher M, Trkola A, Grassauer A, Schulz PM, Klima A, Dopper S, et al. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 1996; 10: 587-593.
172. Conley AJ, Kessler JA, 2nd, Boots LJ, Tung JS, Arnold BA, Keller PM, et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994; 91: 3348-3352.
173. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1
174. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17: 1757-1765.
175. Munoz-Barroso I, Salzwedel K, Hunter E, Blumenthal R. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol 1999; 73: 6089-6092.
176. Salzwedel K, West JT, Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol 1999; 73: 2469-2480.
177. Tian Y, Ramesh CV, Ma X, Naqvi S, Patel T, Cenizal T, et al. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints. J Pept Res 2002; 59: 264-276.
178. Barbato G, Bianchi E, Ingallinella P, Hurni WH, Miller MD, Ciliberto G, et al. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol 2003; 330: 1101-1115.
179. Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, Katinger H, et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001; 75: 10906-10911.
180. McGaughey GB, Citron M, Danzeisen RC, Freidinger RM, Garsky VM, Hurni WM, et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry 2003; 42: 3214-3223.
181. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995; 69: 6609-6617.
182. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-4018.
183. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6: 200-206.
184. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-210.
185. Stiegler G, Armbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. Aids 2002; 16: 2019-2025.
186. Armbruster C, Stiegler GM, Vcelar BA, Jager W, Michael NL, Vetter N, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. Aids 2002; 16: 227-233.
187. Jiang S, Lin K, Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1998; 72: 10213-10217.
188. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994; 68: 4031-4034.
189. Eckhart L, Raffelsberger W, Ferko B, Klima A, Purtscher M, Katinger H, et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen Virol 1996; 77 (Pt 9): 2001-2008.
190. Schibli DJ, Montelaro RC, Vogel HJ. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry 2001; 40: 9570-9578.
191. Biron Z, Khare S, Samson AO, Hayek Y, Naider F, Anglister J. A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biochemistry 2002; 41: 12687-12696.
192. Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, Citron MP, et al. Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 2002; 277: 45811-45820.
193. Pai E, Klein M, Chong P, Pedy-Czak A. Fab-epitope complex from the HIV-1 cross-neutralizing monoclonal antibody 2F5. Patent #WO 00/61618, in http://ipdl.wipo.int 2000; University of Toronto.
194. Louis JM, Nesheiwat I, Chang L, Clore GM, Bewley CA. Covalent Trimers of the Internal N-terminal Trimeric Coiled-coil of gp41 and Antibodies Directed against Them Are Potent Inhibitors of HIV Envelope-mediated Cell Fusion. J Biol Chem 2003; 278: 20278-20285.
195. Watanabe S, Takada A, Watanabe T, Ito H, Kida H, Kawaoka Y. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol 2000; 74: 10194-10201.
196. Daenke S, Booth S. Molecular mechanisms affecting HTLV type 1-dependent fusion at the cell membrane: implications for inhibiting viral transmission. AIDS Res Hum Retroviruses 2000; 16: 1731-1736.
197. Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci USA 1996; 93: 2186-2191.
198. Rapaport D, Ovadia M, Shai Y. A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. EMBO J 1995; 14: 5524-5531.
199. Yao Q, Compans RW. Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. Virology 1996; 223: 103-112.
200. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 2003; 77: 8801-8811.
201. Huang L, Zhang L, Chen CH. Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41. Curr Pharm Design 2003; 9(18): 1453-62.
202. Jiang S, Zhao Q, Debnath AK. Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Design 2002; 8(8): 563-80.
203. Tozser J, Oroszlan S. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr Pharm Design 2003; 9(22): 1803-15.